Sionna Therapeutics Inc (SION)
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis. Its pipeline includes several CFTR-targeted candidates, such as galicaftor (SION-2222) and navocaftor (SION-3067), both of which have completed Phase 2 trials, as well as SION-109 and SION-2851, which have each completed Phase 1 studies. The company is also advancing SION-451 in a Phase 1 trial and SION-719 in a Phase 2a proof-of-concept trial. Founded in 2019 and formerly known as Sling Therapeutics, Inc., Sionna Therapeutics is headquartered in Waltham, Massachusetts. Its common stock is listed on NASDAQ under the symbol SION.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SION
|
$10.60
|
77.8% Upside
|
Bargain
|
$21
|
252.3% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
1.0x
|
269.5 M
|
9.282 M
|
2.4%
|
37.7%
|
9.2
|
78.3%
|
